ClinVar Miner

Submissions for variant NM_000152.5(GAA):c.1003G>A (p.Gly335Arg)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Broad Institute Rare Disease Group,Broad Institute RCV001249005 SCV001422850 pathogenic Glycogen storage disease, type II 2020-01-22 no assertion criteria provided curation The p.Gly335Arg variant in GAA has been reported in four individuals with glycogen storage disease II (PMID: 24685124, 26497565, 18425781), and has been identified in 0.003% (1/30616) of South Asian chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs202095215). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a recessive carrier frequency. In vitro functional studies using COS-7 cells transfected with the variant provide some evidence that the p.Gly335Arg variant may impact protein function (PMID: 22644586). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. A pathogenic variant, resulting in a different amino acid change at the same position, p.Gly335Glu, has been reported in association with the disease in the literature and in ClinVar, slightly supporting that a change at this position may not be tolerated (PMID: 22644586, 24513544, 27649523; VariationID: 180142). The phenotype of an individual heterozygous for this variant is highly specific for glycogen storage disease II based on GAA enzyme activity being <10% of wild type consistent with disease (PMID: 26497565). In summary, this variant meets criteria to be classified as pathogenic for glycogen storage disease II in an autosomal recessive manner based on in vitro functional studies and another pathogenic variant at the same position. ACMG/AMP Criteria applied: PS3, PM2, PP3, PP4, PM5 (Richards 2015).

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.